GlassScriptPhysician profile
Nabarun Sarkar
NPI 1902887599
$6,826.54
in general payments reported to CMS, 2019-2025
34 companies · $997 in 2025
The $997 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,492 · 2020: $233 · 2021: $479 · 2022: $932 · 2023: $1,400 · 2024: $1,295 · 2025: $997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,691.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,224.31 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $1,057.50 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $691.47 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $643.49 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $605.15 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $545.54 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $471.51 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Allergan, INC. | $343.47 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $168.89 | 2022-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $130.07 | 2019 | |
| Axsome Therapeutics, INC. | $109.37 | 2023-2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $106.66 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $104.89 | 2019-2023 | Xarelto |
| Idorsia Pharmaceuticals US INC | $86.33 | 2022-2024 | Quviviq |
| Novartis Pharmaceuticals Corporation | $61.48 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $46.32 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $44.20 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $43.35 | 2022 | |
| Exact Sciences Corporation | $38.49 | 2024 | Cologuard Collection Kit |
| Amgen INC. | $31.47 | 2019-2021 | |
| Amarin Pharma, INC. | $30.93 | 2019 | |
| Ironwood Pharmaceuticals, INC | $29.28 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $27.22 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $24.02 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $23.67 | 2024 | Gvoke Hypopen |
| Lundbeck LLC | $18.49 | 2025 | Rexulti |
| Viatris Specialty LLC | $18.15 | 2025 | Yupelri |
| Avanir Pharmaceuticals, INC. | $17.42 | 2020 | |
| Phathom Pharmaceuticals, INC. | $16.63 | 2024 | Voquezna |
| Tris Pharma INC | $16.20 | 2025 | Dyanavel Xr |
| Kowa Pharmaceuticals America, INC. | $15.29 | 2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $12.00 | 2022 | |
| Abbott Laboratories | $11.79 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nabarun Sarkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.